Eagle Capital Growth Fund Inc (GRF) ニュース

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

SAN CARLOS, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing...

Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash

The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.68 per share in cash. The record...

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on...

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical...

Form 4 - Statement of changes in beneficial ownership of securities

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form N-PX - Annual Report of proxy voting record of management investment companies

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339

GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic...

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for...

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in...

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

With today’s announcement of the transaction completion, Grifols and Haier Group will work together through...

Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies

With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous...